CandidPharm · Ningbo Candid Pharmaceutical Co., Ltd. · 宁波嘉安药业有限公司
CATEGORY C · CP-RELU-01Intermediate

2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylic acid

2-((2,6-二氟苄基)(乙氧基羰基)氨基)-4-((二甲基氨基)甲基)-5-(4-硝基苯基)噻吩-3-羧酸
CAS Registry No.
1589503-95-6
Related API
Relugolix
Molecular Weight
519.5
Product Type
Intermediate

Identification & Structure

Chemical structure of 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylic acid
2D Structure

CCOC(=O)N(CC1=C(C=CC=C1F)F)C2=C(C(=C(S2)C3=CC=C(C=C3)[N+](=O)[O-])CN(C)C)C(=O)O

Product CodeCP-RELU-01
Product TypeIntermediate
CAS Number1589503-95-6
Molecular FormulaC24H23F2N3O6S
Molecular Weight519.5
IUPAC Name2-[(2,6-difluorophenyl)methyl-ethoxycarbonylamino]-4-[(dimethylamino)methyl]-5-(4-nitrophenyl)thiophene-3-carboxylic acid
SMILESCCOC(=O)N(CC1=C(C=CC=C1F)F)C2=C(C(=C(S2)C3=CC=C(C=C3)[N+](=O)[O-])CN(C)C)C(=O)O
InChIKeyWIZSPFRNLVKEOT-UHFFFAOYSA-N
PubChem CID101890000
Quality ParametersRequest current specification and available batch documentation

Related API

Listed in our catalog as an intermediate related to Relugolix.

Specifications and available documentation are reviewed against your project requirements. Availability and lead time are confirmed for each enquiry, taking current stock and production schedules into account.

Direct Inquiries

Request a Quote & Documents

Tell us the quantity, specification and destination. We will reply by email with pricing, lead time and the documents available.

· We will reply by email
· Mutual NDA available on request

Documents on Request

Request current specification and available batch documentation. We will confirm which TDS, SDS, CoA and analytical materials can be shared for this product.

Patent Notice

Supply is reviewed against the destination, patent status and intended use. Products are not offered where the transaction would infringe valid patents or supplementary protection certificates. Where applicable, regulatory-development activities may fall within the Bolar exemption under Article 10(6) of EU Directive 2001/83/EC, as amended by Directive 2004/27/EC, or 35 U.S.C. § 271(e)(1). These provisions have specific conditions; research use alone does not establish an exemption. Buyers must confirm applicable requirements for their jurisdiction and project before ordering. Commercial supply in protected territories requires an applicable legal basis.